The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

Cell biologist Bruce Edgar, recognized for his research on cell growth and proliferation, was elected to the prestigious ...

Viruses are known to use the genetic machinery of the human cells they invade to make copies of themselves. As part of the ...

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

Tumor-treating fields (TTFields) therapy and chemoradiation therapy (CRT) may have significant anti-tumor efficacy in ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

The genome incorporation mechanism for LINE-1, the only autonomously active retrotransposon in humans, leverages the cell ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

A new clinical trial shows the immunotherapy drug dostarlimab may eliminate the need for surgery and chemotherapy in certain ...

Efforts to estimate the reproducibility of published research results have focused on specific areas of research to date, ...

Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio ...